{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T21:37:21Z","timestamp":1777412241853,"version":"3.51.4"},"reference-count":71,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Peripheral T-cell lymphomas (PTCLs) are distinct pathological entities with clinical advancements lagging behind their B-cell lymphoma counterpart. Frequently aggressive in their clinical behaviour, clinicians are constantly challenged with low complete remission rates, early relapses and failure to achieve long-term responses despite aggressive first-line chemotherapy, resulting in poor overall survival in the majority of patients. There is currently no consensus regarding the optimal therapy for PTCL and treatment approaches are mainly derived from prospective phase II studies, registry data and retrospective studies. Despite its biological heterogeneity, a less than satisfactory \u201cone-size-fits-all\u201d approach has been adopted to date. Although its role remains controversial, for many years, haematopoietic stem cell transplantation has been adopted by clinicians with the aim of overcoming poor outcomes by consolidating responses. In this review, we aim to define the role of both autologous and allogeneic stem cell transplantation in PTCL in both frontline and salvage settings, especially in the context of recent advancements in this field.<\/jats:p>","DOI":"10.3390\/cancers12113125","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T10:38:35Z","timestamp":1603708715000},"page":"3125","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8848-9423","authenticated-orcid":false,"given":"Chathuri","family":"Abeyakoon","sequence":"first","affiliation":[{"name":"Epworth HealthCare, Melbourne, Victoria 3002, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"van der Weyden","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Harrop","sequence":"additional","affiliation":[{"name":"Epworth HealthCare, Melbourne, Victoria 3002, Australia"},{"name":"Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Khot","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria 3000, Australia"},{"name":"Royal Melbourne Hospital, Melbourne, Victoria 3052, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Dickinson","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costas K.","family":"Yannakou","sequence":"additional","affiliation":[{"name":"Epworth HealthCare, Melbourne, Victoria 3002, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-2448","authenticated-orcid":false,"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[{"name":"Epworth HealthCare, Melbourne, Victoria 3002, Australia"},{"name":"Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the groupe d\u2019etude des lymphomes de l\u2019adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"Relander","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/clinids\/18.3.421","article-title":"Purpose of quality standards for infectious diseases","volume":"18","author":"Gross","year":"1994","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","article-title":"Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: A prospective study from the Gel-Tamo Study Group","volume":"79","author":"Conde","year":"2007","journal-title":"Eur. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral t-cell lymphomas: Results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1038\/bcj.2016.63","article-title":"First-line therapy of peripheral T-cell lymphoma: Extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation","volume":"6","author":"Wilhelm","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/leu.2014.79","article-title":"Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma","volume":"28","author":"Corradini","year":"2014","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/annonc\/mdu515","article-title":"Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: An intention-to-treat analysis from a single center","volume":"26","author":"Loirat","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","article-title":"High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: The GEL-TAMO experience","volume":"14","author":"Caballero","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: A study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbmt.2013.01.006","article-title":"Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma","volume":"19","author":"Kanakry","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000353778","article-title":"Autologous stem cell transplantation as the first-line treatment for peripheral T cell lymphoma: Results of a comprehensive meta-analysis","volume":"131","author":"Yin","year":"2014","journal-title":"Acta Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.bbmt.2015.01.013","article-title":"Comparison of survival in patients with t cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease","volume":"21","author":"Beitinjaneh","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: An analysis of patients from LYSA centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.bbmt.2015.12.004","article-title":"Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed\/Refractory Setting: A Systematic Review\/Meta-Analysis","volume":"22","author":"Reljic","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s00277-002-0556-2","article-title":"Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation","volume":"81","author":"Kahl","year":"2002","journal-title":"Ann. Hematol."},{"key":"ref_21","first-page":"1272","article-title":"Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation","volume":"88","author":"Schetelig","year":"2003","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1704367","article-title":"Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: A nation-wide survey","volume":"33","author":"Jantunen","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","article-title":"The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: A BSBMT and ABMTRR study","volume":"40","author":"Feyler","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0609.2007.00815.x","article-title":"Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. The GELTAMO experience","volume":"78","author":"Conde","year":"2007","journal-title":"Eur. J. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/annonc\/mdl466","article-title":"The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: The Spanish Lymphoma and Autologous Transplantation Group experience","volume":"18","author":"Conde","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_26","first-page":"218","article-title":"High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: Complete remission at transplantation is the major determinant of outcome\u2014Lymphoma Working Party of the European Group for blood and marrow transplantation","volume":"26","author":"Kyriakou","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hon.853","article-title":"Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas","volume":"26","author":"Niitsu","year":"2008","journal-title":"Hematol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5507\/bp.2009.011","article-title":"Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation","volume":"153","author":"Prochazka","year":"2009","journal-title":"Biomed. Pap."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bbmt.2008.11.010","article-title":"Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell Lymphoma, Unspecified: Complete Remission at Transplantation and the Prognostic Index of Peripheral T Ce","volume":"15","author":"Yang","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/bmt.2009.165","article-title":"Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: Retrospective analysis of the experience of the Fukuoka BMT group","volume":"45","author":"Numata","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5507\/bp.2011.009","article-title":"Long-term outcome of patients with peripheral t-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation","volume":"155","author":"Prochazka","year":"2011","journal-title":"Biomed. Pap."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.bbmt.2011.02.008","article-title":"High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphoma (PTCL): Analysis of Prognostic Factors","volume":"17","author":"Nademanee","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00277-013-1716-2","article-title":"Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: Long-term outcome and risk factors analysis","volume":"92","author":"Czyz","year":"2013","journal-title":"Ann. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.clml.2013.07.005","article-title":"A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission","volume":"13","author":"Mehta","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12185-013-1465-y","article-title":"High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: Treatment outcome and prognostic factor analysis","volume":"99","author":"Gui","year":"2014","journal-title":"Int. J. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Gritti, G., Boschini, C., Rossi, A., Delaini, F., Grassi, A., Algarotti, A., Mic\u00f2, C., Trezzi, R., Gianatti, A., and Barbui, A.M. (2015). Primary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121822"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ajh.24372","article-title":"Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas","volume":"91","author":"Yam","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/0300060516676725","article-title":"Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience","volume":"45","author":"Han","year":"2017","journal-title":"J. Int. Med. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7150\/ijms.23067","article-title":"Outcome and prospective factor analysis of high-dose therapy combined with autologous peripheral blood stem cell transplantation in patients with peripheral T-cell lymphomas","volume":"15","author":"Wu","year":"2018","journal-title":"Int. J. Med. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: A study by the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire","volume":"26","author":"Milpied","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Epperla, N., Ahn, K.W., Litovich, C., Ahmed, S., Battiwalla, M., Cohen, J.B., Dahi, P., Farhadfar, N., Farooq, U., and Freytes, C.O. (2019). Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: A CIBMTR analysis. J. Hematol. Oncol., 12.","DOI":"10.1186\/s13045-018-0696-z"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s12185-019-02748-1","article-title":"Successful outcome with reduced-intensity condition regimen followed by allogeneic hematopoietic stem cell transplantation for relapsed or refractory anaplastic large-cell lymphoma","volume":"110","author":"Fukano","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","article-title":"Long-Term Results of Autologous Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma: The Stanford Experience","volume":"14","author":"Chen","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","article-title":"Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma","volume":"134","author":"Kewalramani","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: A retrospective study from the lymphoma working party of the European group for blood and marrow transplantation","volume":"27","author":"Kyriakou","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2141.2010.08210.x","article-title":"Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas","volume":"150","author":"Shustov","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/annonc\/mdq698","article-title":"A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides\/Sezary syndrome","volume":"22","author":"Jacobsen","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3109\/10428194.2011.574754","article-title":"Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control","volume":"52","author":"Zain","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/bmt.2011.16","article-title":"Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas","volume":"47","author":"Delioukina","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","article-title":"Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: Long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect","volume":"26","author":"Dodero","year":"2012","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3109\/10428194.2011.645818","article-title":"Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant","volume":"53","author":"Goldberg","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.bbmt.2013.07.003","article-title":"Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-hodgkin\u2019s lymphoma","volume":"19","author":"Czajczynska","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.bbmt.2017.04.021","article-title":"Outcome of Allogeneic and Autologous Hematopoietic Cell Transplantation for High-Risk Peripheral T Cell Lymphomas: A Retrospective Analysis From a Chinese Center","volume":"23","author":"Huang","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00277-018-3288-7","article-title":"The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: A real-world experience","volume":"97","author":"Rohlfing","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_57","unstructured":"(2020, August 13). NCCN Clinical Practice Guidelines in OncologyTM. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/t-cell.pdf."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","article-title":"Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK\/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Ma","volume":"23","author":"Kumar","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_59","first-page":"v108","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Gaulard","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral t-cell lymphoma patients failing first-line therapy: A report from the prospective, international t-cell project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1182\/blood-2018-99-110429","article-title":"Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant","volume":"132","author":"Relander","year":"2018","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Wulf, G.G., Altmann, B., Ziepert, M., D\u2019Amore, F., Held, G., Greil, R., Tournilhac, O., Relander, T., Viardot, A., and Wilhelm, M. (2020). Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: The DSHNHL2006-1B\/ACT-2 trial. Leukemia, 1\u20133.","DOI":"10.1038\/s41375-020-0838-5"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2009-07-231324","article-title":"Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation","volume":"115","author":"Sieniawski","year":"2010","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41409-018-0294-2","article-title":"High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: A UK NCRI\/Cancer Research UK Phase II Study","volume":"54","author":"Phillips","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood-2012-11-466839","article-title":"Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: A retrospective study by the EBMT","volume":"121","author":"Jantunen","year":"2013","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.23992","article-title":"Treatment response in enteropathy associated T-cell lymphoma; survival in a large multicenter cohort","volume":"90","author":"Nijeboer","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2014.280","article-title":"Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: A retrospective study of the EBMT Lymphoma Working Party","volume":"29","author":"Tanase","year":"2015","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1038\/bcj.2015.43","article-title":"Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma","volume":"5","author":"Rashidi","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1365-2141.2000.02098.x","article-title":"Autologous stem cell transplantation for anaplastic large- cell lymphomas: Results of a prospective trial","volume":"109","author":"Deconinck","year":"2000","journal-title":"Br. J. Haematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/11\/3125\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:28:16Z","timestamp":1760178496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/11\/3125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,26]]},"references-count":71,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["cancers12113125"],"URL":"https:\/\/doi.org\/10.3390\/cancers12113125","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,26]]}}}